18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors

Journal of Nuclear Medicine

Volumn 52, Issue 2, 2011, Pages 270-278

  Honer, Michael ^a   Mu, Linjing ^a   Stellfeld, Timo ^b   Graham, Keith ^b   Martic, Miljen ^a   Fischer, Cindy R ^a   Lehmann, Lutz ^b   Schubiger, Pius A ^a   Ametamey, Simon M ^a   Dinkelborg, Ludger ^b   Srinivasan, Ananth ^b   Borkowski, Sandra ^b  

^a ETH Zurich   (Switzerland)

^b BAYER PHARMA AG   (Germany)

Author keywords

Bombesin; Choline; GRPr; LNCaP; PC 3; PET

Indexed keywords

BAY 86 4367 F 18; BOMBESIN DERIVATIVE; FLUORETHYLCHOLINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; TRACER; UNCLASSIFIED DRUG; BAY 86 4367; BAY 86-4367; BOMBESIN; BOMBESIN RECEPTOR; CYSTEIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR AFFINITY; URINARY EXCRETION; ANIMAL; BINDING COMPETITION; CANCER TRANSPLANTATION; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BINDING, COMPETITIVE; BOMBESIN; CELL LINE; CYSTEIC ACID; DRUG STABILITY; FLUORINE RADIOISOTOPES; HUMANS; INDICATORS AND REAGENTS; ISOTOPE LABELING; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 79851506832     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081620     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Hong H, Zhang Y, Sun JT, Cai WB. Positron emission tomography imaging of prostate cancer. Amino Acids. 2010;39:11-27.
3. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006;36:51-72. (Pubitemid 41779367)
4. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate cancer imaging. Eur J Radiol. 2009;70:212-226.
5. 4) bombesin by tumor-cells. Prostate. 1994;25:29-38.
6. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159. (Pubitemid 29135980)
7. Chung DH, Evers BM, Beauchamp RD, et al. Bombesin stimulates growth of human gastrinoma. Surgery. 1992;112:1059-1065. (Pubitemid 23008232)
8. Hoffman TJ, Gali H, Smith CJ, et al. Novel series of In-111-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823-831. (Pubitemid 39655218)
9. Maecke HR, Hofmann M, Haberkorn U. Ga-68-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl):172S-178S.
10. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a Cu-64-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763. (Pubitemid 36875435)
11. 3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem. 2008;19:2432-2439.
12. Schroeder RPJ, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods. 2009;48:200-204.
13. Nock B, Nikolopoulou A, Chiotellis E, et al. [Tc-99m]demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:247-258. (Pubitemid 36686844)
14. Mansi R, Wang XJ, Forrer F, et al. Evaluation of a 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
15. Zhang XZ, Cai WB, Cao F, et al. F-18-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501. (Pubitemid 46768492)
16. Hoehne A, Mu L, Honer M, et al. Synthesis, F-18-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem. 2008;19:1871-1879.
17. Li ZB, Wu ZH, Chen K, Ryu EK, Chen XY. F-18-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008;49:453-461. (Pubitemid 351355212)
18. Liu ZF, Yan YJ, Liu SL, Wang F, Chen XY. F-18, Cu-64, and Ga-68 labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016-1025.
19. 18F- labeling of peptides via nucleophilic aromatic substitution. Bioconjug Chem. 2009;20:2254-2261.
20. Mu L, Honer M, Becaud J, et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem. 2010;21:1864-1871.
21. 76Br-bromocaramiphen. J Labelled Comp Radiopharm. 1996;42:447-456.
22. Honer M, Bruhlmeier M, Missimer J, Schubiger AP, Ametamey SM. Dynamic imaging of striatal D-2 receptors in mice using quad-HIDAC PET. J Nucl Med. 2004;45:464-470. (Pubitemid 47618622)
23. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326. (Pubitemid 351225672)
24. 5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502-511.
25. Ginj M, Zhang HW, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441. (Pubitemid 44715214)
26. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjug Chem. 2004;15:1416-1423. (Pubitemid 39552033)
27. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
28. Nock BA, Nikolopoulou A, Galanis A, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with Tc-99m: a preclinical study. J Med Chem. 2005;48:100-110. (Pubitemid 40109510)
29. Gourni E, Paravatou M, Bouziotis P, et al. Evaluation of a series of new Tc-99m-labeled bombesin-like peptides for early cancer detection. Anticancer Res. 2006;26:435-438. (Pubitemid 43206110)
30. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of Cu-64-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110-1117.
31. Mu L, Hohne A, Schubiger RA, et al. Silicon-based building blocks for one-step F-18-radiolabeling of peptides for PET imaging. Angew Chem Int Ed. 2008;47:4922-4925.
32. Schirrmacher R, Bradtmoller G, Schirrmacher E, et al. F-18-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed. 2006;45:6047-6050. (Pubitemid 44408699)
33. Roehn U, Becaud J, Mu LJ, et al. Nucleophilic ring-opening of activated aziridines: a one-step method for labeling biomolecules with fluorine-18. J Fluor Chem. 2009;130:902-912.
34. Abd-Elgaliel WR, Gallazzi F, Garrison JC, et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as a targeting vector. Bioconjug Chem. 2008;19:2040-2048.